Deantigenation of human type B erythrocytes with Glycine max alpha-D-galactosidase

Cicer α-galactosidase immobilization onto chitosan and Amberlite MB-150: optimization, characterization, and its applications

Cicer α-galactosidase was immobilized onto chitosan and Amberlite with immobilization efficiency of 62% and 51%, respectively. Compared to soluble enzyme, immobilized enzyme had a broader operational pH range and thermal stability. Temperature optimum for chitosan immobilized enzyme and Amberlite immobilized enzyme was 70°C, whereas it was 50°C for soluble enzyme. After 120days storage at 4°C chitosan immobilized enzyme retained 54% activity and Amberlite immobilized enzyme showed 32% activity. After using the immobilized enzymes 12 times, chitosan immobilized enzyme showed 52% activity, while Amberlite immobilized enzyme retained 22% activity with pNPGal. The immobilized enzyme exhibited higher K(m) compared to the soluble enzyme. Raffinose family oligosaccharides (RFOs) are mainly responsible for flatulence on taking of soybean derived food products. Immobilized enzyme can be used effectively for the hydrolysis of RFOs. After five runs, chitosan and Amberlite immobilized enzyme retained 53% and 34% activity, respectively with soybean RFOs. The easy availability of enzyme source, ease of its immobilization on matrices, non-toxicity and low cost of matrices, increased stability of immobilized enzyme, and effective hydrolysis of RFOs makes it a suitable product with potential applications at industries.

Transfusion to blood group A and O patients of group B RBCs that have been enzymatically converted to group O

BACKGROUND

The transfusion of ABO-incompatible RBCs is the leading cause of fatal transfusion reactions. Group O RBCs, lacking terminal immunodominant A and B sugars to which humans are immunized, are safe for transfusion to persons of any ABO blood group. With the use of a recombinant alpha-galactosidase to remove terminal galactose from group B RBCs, the safety and efficacy of enzyme-converted group-B-to-group-O (ECO) RBC components were studied in transfusion-dependent patients.

STUDY DESIGN AND METHODS

Twenty-four patients (blood groups A and O) were randomly assigned to receive transfusion(s) of either ECO or control group O RBCs. If a second transfusion was given, the other blood component was administered.

RESULTS

Twenty-one patients were given ECO RBCs; 18 also underwent control transfusions. One patient received only a small aliquot for RBC survival studies, instead of a full-unit transfusion, because his serum was incompatible with ECO RBCs. No adverse events occurred. Both ECO and control transfusions resulted in appropriate Hb increments and comparable (51)Cr-labeled RBC survival studies. One patient developed a transient, weak-positive DAT, without hemolysis. Two weeks after transfusion, 5 of 19 evaluable ECO RBC recipients had increases in anti-B titers.

CONCLUSION

ECO RBCs were comparable to group O cells for safety and efficacy in this study. The clinical significance of the increase in anti-B and of occasional serologic incompatibilities with ECO RBCs is unclear. If strategies can be developed to remove A epitopes, enzymatic conversion could be used to create a universal (group O) donor blood supply.